Direct-acting antivirals and viral RNA targeting for hepatitis B cure - Centre de recherche en cancérologie de Lyon (UMR INSERM 1052 ; CNRS 5286 ; Centre Léon Bérard) Accéder directement au contenu
Article Dans Une Revue Current Opinion in HIV and AIDS Année : 2020

Direct-acting antivirals and viral RNA targeting for hepatitis B cure

Résumé

Purpose of review: The current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues and IFN are effective at viral suppression but very poor at achieving HBsAg loss. This article is designed to summarize the HBV life cycle in order to review the current treatment strategies and compounds targeting different points of the virus life cycle, which are either in preclinical or clinical phases. Recent findings: Recently our developed understanding of the HBV life cycle has enabled the development of multiple novel treatment options, all aiming for functional cure. Summary: It is likely that combinations of novel treatments will be needed to achieve a functional cure, including those that target the virus itself as well as those that target the immune system.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-03932952 , version 1 (10-01-2023)

Identifiants

Citer

Janine French, Stephen Locarnini, Fabien Zoulim. Direct-acting antivirals and viral RNA targeting for hepatitis B cure. Current Opinion in HIV and AIDS, 2020, 15 (3), pp.165-172. ⟨10.1097/COH.0000000000000622⟩. ⟨hal-03932952⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More